BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Peter Bossuyt, Filip Baert, Francois D’Heygere, Antoine Nakad, Catherine Reenaers, Fernand Fontaine, Denis Franchimont, Olivier Dewit, Philippe Van Hootegem, Stijn Vanden Branden, Guy Lambrecht, Marc Ferrante, Pieter Hindryckx, Elisabeth Macken, Philip Caenepeel, Anne Vijverman, Nicolas de Suray, Joris Dutré, Edouard Louis, Jean-Louis Coenegracths. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART CohortInflammatory Bowel Diseases 2019; 25(1): 156 doi: 10.1093/ibd/izy219
2
George Philip, Freddy Cornillie, J Omoniyi Adedokun, Richard Melsheimer, Paul Rutgeerts, Jean-Frédéric Colombel, Colleen Marano. Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic DataJournal of Crohn's and Colitis 2019; 13(10): 1257 doi: 10.1093/ecco-jcc/jjz052
3
G. Trejo, A. Marco-Marqués, S.V. Hernández, M.M. Boscá-Watts. Investigación clínica en 2016: artículos destacadosEnfermedad Inflamatoria Intestinal al Día 2017; 16(3): 106 doi: 10.1016/j.eii.2017.03.002
4
Jimmy K Limdi. Golimumab for ulcerative colitis: adding perspective to the pursuitFrontline Gastroenterology 2018; 9(3): 232 doi: 10.1136/flgastro-2017-100929
5
Anne S. Strik, Sophie E. Berends, Ron A. Mathôt, Geert R. D’Haens, Mark Löwenberg. Golimumab for moderate to severe ulcerative colitisExpert Review of Gastroenterology & Hepatology 2017; 11(5): 401 doi: 10.1080/17474124.2017.1303376
6
GolimumabReactions Weekly 2017; 1642(1): 145 doi: 10.1007/s40278-017-27322-0
7
Beatrice Orlandini, Gabriele Dragoni, Angela Variola, Arianna Massella, Siro Bagnoli, Riccardo Campi, Francesca Rogai. Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centersJournal of Digestive Diseases 2018; 19(8): 468 doi: 10.1111/1751-2980.12648
8
Iris Detrez, Ganel Schops, Jolien Lefrère, Sophie Tops, Gert Van Assche, Séverine Vermeire, Wouter Van Moerkercke, Marc Ferrante, Ann Gils. Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic InformationThe AAPS Journal 2019; 21(1) doi: 10.1208/s12248-018-0282-x
9
Georgina Cunningham, Mark A. Samaan, Peter M. Irving. Golimumab in the treatment of ulcerative colitisTherapeutic Advances in Gastroenterology 2019; 12: 175628481882126 doi: 10.1177/1756284818821266
10
David Olivares, Cristina Alba, Irene Pérez, Valentín Roales, Enrique Rey, Carlos Taxonera. Differences in the need for adalimumab dose optimization between Crohn�s disease and ulcerative colitisRevista Española de Enfermedades Digestivas 2019; 111 doi: 10.17235/reed.2019.6148/2018
11
Fabrizio Bossa, Giuseppe Biscaglia, Maria Rosa Valvano, Giuseppe Costantino, Angelo Lauria, Rocco Clemente, Concetta Ferracane, Endrit Shahini, Marco Mendolaro, Laurino Grossi, Silvia Mazzuoli, Antonio Rispo, Giuseppe Pranzo, Ladislava Sebkova, Antonio Tursi, Agnese Miranda, Marta Patturelli, Rocco Spagnuolo, Cristina Ricciardelli, Caterina Sgarro, Pietro Paese, Gaetano Inserra, Alessandro Azzarone, Olga Nardone, Walter Fries, Nello Buccianti, Antonino Carlo Privitera, Maria Beatrice Principi, Maria Cappello, Francesco William Guglielmi, Marco Romano, Gabriele Riegler, Libera Fanigliulo, Raffaele Melina, Angelo Andriulli. Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative ColitisDigestive Diseases and Sciences 2020; 65(6): 1767 doi: 10.1007/s10620-019-05904-z
12
Javier P Gisbert, María Chaparro. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical PracticeJournal of Crohn's and Colitis 2020; 14(5): 694 doi: 10.1093/ecco-jcc/jjz195
13
Mark A Samaan, Polychronis Pavlidis, Jonathan Digby-Bell, Emma L Johnston, Angad Dhillon, Ramesh Paramsothy, Abisoye O Akintimehin, Lucy Medcalf, Guy Chung-Faye, Patrick DuBois, Ioannis Koumoutsos, Nick Powell, Simon H C Anderson, Jeremy Sanderson, Bu’ Hussain Hayee, Peter M Irving. Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centresFrontline Gastroenterology 2018; 9(3): 221 doi: 10.1136/flgastro-2017-100895
14
Carlos Taxonera, Marisa Iborra, Marta Maia Bosca-Watts, Saioa Rubio, Óscar Nantes, Rebeca Higuera, Federico Bertoletti, Pilar Martínez-Montiel, Mónica Sierra-Ausin, Noemí Manceñido, José Lázaro Pérez-Calle, Alicia Algaba, David Olivares, Cristina Alba. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitisCurrent Medical Research and Opinion 2019; 35(7): 1297 doi: 10.1080/03007995.2019.1579557
15
Jim O’Connell, Cathy Rowan, Roisin Stack, Grace Harkin, Vikrant Parihar, Grace Chan, Niall Breslin, Garret Cullen, Cara Dunne, Laurence Egan, Gavin Harewood, Jan Leyden, Finbar MacCarthy, Padraic MacMathuna, Nasir Mahmud, Susan McKiernan, Deirdre McNamara, Hugh Mulcahy, Frank Murray, Anthony O’Connor, Aoibhlinn O’Toole, Stephen Patchett, Barbara Ryan, Juliette Sheridan, Eoin Slattery, Glen Doherty, David Kevans. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitisEuropean Journal of Gastroenterology & Hepatology 2018; 30(9): 1019 doi: 10.1097/MEG.0000000000001177
16
Abhinav Vasudevan, Peter R Gibson, Daniel R van Langenberg. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?World Journal of Gastroenterology 2017; 23(35): 6385-6402 doi: 10.3748/wjg.v23.i35.6385
17
Gabriele Dragoni, Marco Le Grazie, Beatrice Orlandini, Francesca Rogai. Golimumab in inflammatory bowel diseases: present and future scenariosClinical Journal of Gastroenterology 2019; 12(1): 1 doi: 10.1007/s12328-018-0906-9
18
Carlos Taxonera, Cristina Rodríguez, Federico Bertoletti, Luís Menchén, Julia Arribas, Mónica Sierra, Lara Arias, Pilar Martínez-Montiel, Alba Juan, Eva Iglesias, Alicia Algaba, Noemí Manceñido, Montserrat Rivero, Manuel Barreiro-de Acosta, Pilar López-Serrano, Federico Argüelles-Arias, Ana Gutierrez, David Busquets, Javier P. Gisbert, David Olivares, Marta Calvo, Cristina Alba. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative ColitisInflammatory Bowel Diseases 2017; 23(8): 1394 doi: 10.1097/MIB.0000000000001144
19
Pablo Olivera, Silvio Danese, Lieven Pouillon, Stefanos Bonovas, Laurent Peyrin-Biroulet. Effectiveness of golimumab in ulcerative colitis: A review of the real world evidenceDigestive and Liver Disease 2019; 51(3): 327 doi: 10.1016/j.dld.2018.11.002